


# Kiniksa Pharmaceuticals Ltd. Class A (Fri, May 24, 2024)

Hold candidate since May 24, 2024

StockInvest.us  
Gyneju st. 14, "ROCKIT"  
Vilnius, LT-01109  
Lithuania



## Tech commentaries:

The **Kiniksa Pharmaceuticals Ltd. Class A** stock price fell by **-0.626%** on the last day (Friday, 24th May 2024) from **\$19.17** to **\$19.05**. It has now fallen 6 days in a row. During the last trading day the stock fluctuated **2.57%** from a day low at **\$19.03** to a day high of **\$19.52**. The price has fallen in 7 of the last 10 days and is down by **-2.46%** for this period. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by **-84 thousand** shares and in total, **183** thousand shares were bought and sold for approximately **\$3.49** million.

The stock lies in the middle of a wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall **-7.04%** during the next 3 months and, with a 90% probability hold a price between **\$15.11** and **\$18.61** at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

The **Kiniksa Pharmaceuticals Ltd. Class A** stock holds a sell signal from the short-term Moving Average; at the same time, however, there is a buy signal from the long-term average. Since the short-term average is above the long-term average there is a general buy signal in the stock giving a positive forecast for the stock. On further gains, the stock will meet resistance from the short-term Moving Average at approximately **\$19.49**. On a fall, the stock will find some support from the long-term average at approximately **\$18.67**. A break-up through the short-term average will send a buy signal, whereas a breakdown through the long-term average will send a sell signal. Some negative signals were issued as well, and these may have some influence on the near short-term development. A sell signal was issued from a pivot top point on **Tuesday, May 07, 2024**, and so far it has fallen -6.30%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements.

**Kiniksa Pharmaceuticals Ltd. Class A** finds support from accumulated volume at **\$18.72** and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested. On the upside the stock meets some resistance just above today's level from accumulated volume at **\$19.97**, **\$19.99** and **\$20.19**.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved **\$0.490** between high and low, or **2.57%**. For the last week, the stock has had daily average volatility of **2.10%**.

**Kiniksa Pharmaceuticals Ltd. Class A** holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development. We have upgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Hold/Accumulate candidate.

**Risk: Medium**

Disclaimer: StockInvest.us is a research service that provides financial data and technical analysis of stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "StockInvest.us". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy.